CA 125 Blood Test
The CA 125 Blood Test and Ovarian Cancer
Thet CA 125 Blood Test is normally used to determine the condition of patients suffering from ovarian cancer, as 80 to 90% of those with ovarian cancer in advanced stages will have this enzyme in their blood as a marker. The screening process may not be precise enough to use in women for cancer screening, particularly premenopausal women, since many other circumstances can cause the levels of CA125 to increase. These factors include: Cirrhosis, pelvic inflammatory disease, endometriosis as well as normal menstruation and pregnancy. Hence, the screening is not as particular or sensitive as would idealistic. This entails “false negative” and “false positive” results can occur as the result of a CA125 test, and at intolerably high grades when applied as part of common screening tests such as Pap Smears and mammograms). Note: We advocate the use of thermography instead of mammograms whenver possible.
CA 125 is commonly calculated from a blood sampling. It can even be determined using liquid from the abdominal cavity or chest. The tests presently in use depend upon the usage of a protein that is antagonistic to the CA125 protein. The usual rates for CA 125 may differ slightly from one laboratory to the next. The usual value is not above 35 U/ml.
Blood grades of this supermolecule can be modified in different malignant and benign terms. The most frequent occurrence in which CA125 is made use of is in the supervision of patients with a cancer known, or one of the many tests in the progress of a patient where the certainty of a tumor is unknown.
The CA 125 value can be monitored at steady intervals. A falling level commonly shows that therapy including chemotherapy, has been efficient, where a growing value may indicate the recurrence of a tumour. Because of test fluctuation, small variances are commonly disregarded. A repeating or dividing of the former value is significant.
The patient being diagnosed for pelvic mass, who has a CA125 value above than 65, is often considered to have malignity (in roughly about 90% of examples). Nevertheless, without a provable mass, the affiliation is weaker. CA125 screening may be applied based on symptoms along with other screenings such as as vaginal ultrasound to supervise the advancement of cancer patients.
The CA 125 Blood Test should not be used alone to detect ovarian cancer, but rather with transvaginal sonography and rectovaginal pelvic examination for greater accuracy. The CA 125 blood test should be done serially for the best accuracy.
In 1996, an advanced edition of the test was denoted as CA125-II.
CA 125 is commonly calculated from a blood sampling. It can even be determined using liquid from the abdominal cavity or chest. The tests presently in use depend upon the usage of a protein that is antagonistic to the CA125 protein. The usual rates for CA 125 may differ slightly from one laboratory to the next. The usual value is not above 35 U/ml.
The CA 125 value can be monitored at steady intervals. A falling level commonly shows that therapy including chemotherapy, has been efficient, where a growing value may indicate the recurrence of a tumor. Because of test fluctuation, small variances are commonly disregarded. A repeating or dividing of the former value is significant.
The patient being diagnosed for pelvic mass, who has a CA125 value above than 65, is often considered to have malignity (in roughly about 90% of examples). Nevertheless, without a provable mass, the affiliation is weaker. CA125 screening may be applied based on symptoms along with other screenings such as as vaginal ultrasound to supervise the advancement of cancer patients.
The CA 125 Blood Test should not be used alone to detect ovarian cancer, but rather with transvaginal sonography and rectovaginal pelvic examination for greater accuracy. The CA 125 blood test should be done serially for the best accuracy. According to Snopes, the test alone is not sufficient; other methods should be employed to form the most accurate picture.